Transcutaneous Electroacupuncture for Gastric Complications of Scleroderma

Sponsor
Johns Hopkins University (Other)
Overall Status
Completed
CT.gov ID
NCT03294616
Collaborator
(none)
23
1
3
33.4
0.7

Study Details

Study Description

Brief Summary

An innovative method of needleless transcutaneous electroacupuncture (TEA) using a newly developed watch-size stimulator is proposed. Weak electrical current will be delivered via skin surface electrodes to acupuncture points related to gastrointestinal functions. The stimulator can be attached to the skin near the acupuncture points and therefore daily activity of the patient does not need to be altered. Two experiments are designed to prove the feasibility of the proposed therapy for gastric complications of Scleroderma .

Condition or Disease Intervention/Treatment Phase
  • Device: transcutaneous electroacupuncture
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
23 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
Triple (Participant, Care Provider, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Transcutaneous Electroacupuncture for Gastric Complications of Scleroderma
Actual Study Start Date :
Feb 6, 2017
Actual Primary Completion Date :
Jun 30, 2019
Actual Study Completion Date :
Nov 20, 2019

Arms and Interventions

Arm Intervention/Treatment
Experimental: scleroderma patients-0

for acute study: The experiment in patients will be performed in 4 randomized sessions on separate days (at least 3 days apart): one control session with sham-TEA and 3 TEA sessions at various parameters. TEA will be applied on both acupoints ST36 and PC6; the following sets of parameters will be tested for TEA at ST36: A) standard parameters: the set used in the previous SSc study: 25 Hz, 0.3ms, 2s-on and 3s-off; B) same as A but pulse width of 0.6ms; C) same as B but 0.1s-on and 0.4s-off. For TEA at PC6, 25 Hz will be replaced by 100Hz because TEA at PC6 is used to treat symptoms and 100Hz is believed to be better than 25Hz. The patient will be fasted overnight, and the test will last 2 hours (1 hour fasting and 1 hour postprandial).

Device: transcutaneous electroacupuncture
Weak electrical current will be generated by the device and delivered via skin surface electrodes to acupuncture points related to gastrointestinal functions
Other Names:
  • TEA
  • Experimental: scleroderma patient-1

    for chronic study: 2 weeks of Sham transcutaneous electroacupuncture treatment, 2 weeks of wash out, 2 weeks of transcutaneous electroacupuncture/Sham transcutaneous electroacupuncture treatment. Best parameter gained from acute study will be used.

    Device: transcutaneous electroacupuncture
    Weak electrical current will be generated by the device and delivered via skin surface electrodes to acupuncture points related to gastrointestinal functions
    Other Names:
  • TEA
  • Experimental: scleroderma patients-2

    for chronic study: 2 weeks of transcutaneous electroacupuncture treatment, 2 weeks of wash out, 2 weeks of transcutaneous electroacupuncture/Sham transcutaneous electroacupuncture treatment. Best parameter gained from acute study will be used.

    Device: transcutaneous electroacupuncture
    Weak electrical current will be generated by the device and delivered via skin surface electrodes to acupuncture points related to gastrointestinal functions
    Other Names:
  • TEA
  • Outcome Measures

    Primary Outcome Measures

    1. effect of TEA on symptoms in Systemic Sclerosis (SSc) patients [1 day]

      On the first visit; The validated UCLA SCTC GIT2.0 ("University of California at Los Angeles Scleroderma Clinical Trials Consortium Gastro-Intestinal Tract Instrument version 2.0") for SSc will be the primary outcome measurement; it includes 7 categories: reflux, distention and bloating, fecal soilage, diarrhea, social functioning, emotional well-being and constipation

    2. effect of TEA on symptoms in Systemic Sclerosis (SSc) patients [28 days]

      On the second visit; The validated "University of California at Los Angeles Scleroderma Clinical Trials Consortium Gastro-Intestinal Tract Instrument version 2.0" (UCLA SCTC GIT2.0) for SSc will be the primary outcome measurement; it includes 7 categories: reflux, distention and bloating, fecal soilage, diarrhea, social functioning, emotional well-being and constipation

    3. effect of TEA on symptoms in Systemic Sclerosis (SSc) patients [42 days]

      On the third visit; The validated UCLA SCTC GIT2.0 ("University of California at Los Angeles Scleroderma Clinical Trials Consortium Gastro-Intestinal Tract Instrument version 2.0") for SSc will be the primary outcome measurement; it includes 7 categories: reflux, distention and bloating, fecal soilage, diarrhea, social functioning, emotional well-being and constipation

    4. effect of TEA on symptoms in Systemic Sclerosis (SSc) patients [70 days]

      The validated UCLA SCTC GIT2.0 ("University of California at Los Angeles Scleroderma Clinical Trials Consortium Gastro-Intestinal Tract Instrument version 2.0") for SSc will be the primary outcome measurement; it includes 7 categories: reflux, distention and bloating, fecal soilage, diarrhea, social functioning, emotional well-being and constipation

    5. effect of TEA on symptoms in Systemic Sclerosis (SSc) patients [1 day]

      Scleroderma Health Assessment Questionnaire will be used to assess SSc symptoms

    6. effect of TEA on symptoms in Systemic Sclerosis (SSc) patients [28 days]

      Scleroderma Health Assessment Questionnaire will be used to assess SSc symptoms

    7. effect of TEA on symptoms in Systemic Sclerosis (SSc) patients [42 days]

      Scleroderma Health Assessment Questionnaire will be used to assess SSc symptoms

    8. effect of TEA on symptoms in Systemic Sclerosis (SSc) patients [70 days]

      Scleroderma Health Assessment Questionnaire will be used to assess SSc symptoms

    9. effect of TEA on symptoms in Systemic Sclerosis (SSc) patients [1 day]

      SF-36 questionnaire will be used to assess general quality of life

    10. effect of TEA on symptoms in Systemic Sclerosis (SSc) patients [28 days]

      SF-36 questionnaire will be used to assess general quality of life

    11. effect of TEA on symptoms in Systemic Sclerosis (SSc) patients [42 days]

      SF-36 questionnaire will be used to assess general quality of life

    12. effect of TEA on symptoms in Systemic Sclerosis (SSc) patients [70 days]

      SF-36 questionnaire will be used to assess general quality of life

    13. effect of TEA on symptoms in Systemic Sclerosis (SSc) patients [1 day]

      a validated method including 9 symptoms will be used to assess GI symptoms

    14. effect of TEA on symptoms in Systemic Sclerosis (SSc) patients [28 days]

      a validated method including 9 symptoms will be used to assess GI symptoms

    15. effect of TEA on symptoms in Systemic Sclerosis (SSc) patients [42 days]

      a validated method including 9 symptoms will be used to assess GI symptoms

    16. effect of TEA on symptoms in Systemic Sclerosis (SSc) patients [70 days]

      a validated method including 9 symptoms will be used to assess GI symptoms

    Secondary Outcome Measures

    1. effects of TEA on gastric motility [1 week]

      visit 1 in acute phase; gastric slow waves recording

    2. effects of TEA on gastric motility [2 weeks]

      visit 2 in acute phase; gastric slow waves recording

    3. effects of TEA on gastric motility [3 weeks]

      visit 3 in acute phase; gastric slow waves recording

    4. effects of TEA on gastric motility [4 weeks]

      visit 4 in acute phase; gastric slow waves recording

    5. effects of TEA on autonomic function [1 week]

      visit 1 in acute phase; heart rate variability recording

    6. effects of TEA on autonomic function [2 weeks]

      visit 2 in acute phase; heart rate variability recording

    7. effects of TEA on autonomic function [3 weeks]

      visit 3 in acute phase; heart rate variability recording

    8. effects of TEA on autonomic function [4 weeks]

      visit 4 in acute phase; heart rate variability recording

    9. effects of TEA on gastric motility [1 day]

      visit 1 in chronic phase; gastric slow waves recording

    10. effects of TEA on gastric motility [28 days]

      visit 2 in chronic phase; gastric slow waves recording

    11. effects of TEA on gastric motility [42 days]

      visit 3 in chronic phase; gastric slow waves recording

    12. effects of TEA on gastric motility [70 days]

      visit 4 in chronic phase; gastric slow waves recording

    13. effects of TEA on gastric motility [1 day]

      visit 1 in chronic phase; breath test will be used to assess gastric emptying

    14. effects of TEA on gastric motility [28 days]

      visit 2 in chronic phase; breath test will be used to assess gastric emptying

    15. effects of TEA on gastric motility [42 days]

      visit 3 in chronic phase; breath test will be used to assess gastric emptying

    16. effects of TEA on gastric motility [70 days]

      visit 4 in chronic phase; breath test will be used to assess gastric emptying

    17. effects of TEA on autonomic function [1 day]

      visit 1 in chronic phase; heart rate variability recording

    18. effects of TEA on autonomic function [28 days]

      visit 2 in chronic phase; heart rate variability recording

    19. effects of TEA on autonomic function [42 days]

      visit 3 in chronic phase; heart rate variability recording

    20. effects of TEA on autonomic function [70 days]

      visit 4 in chronic phase; heart rate variability recording

    21. effects of TEA on autonomic function [1 day]

      visit 1 in chronic phase; Composite Autonomic Symptoms Score (COMPASS) 31 survey will be used to assess autonomic function

    22. effects of TEA on autonomic function [28 days]

      visit 2 in chronic phase; Composite Autonomic Symptoms Score (COMPASS) 31 survey will be used to assess autonomic function

    23. effects of TEA on autonomic function [42 days]

      visit 3 in chronic phase; Composite Autonomic Symptoms Score (COMPASS) 31 survey will be used to assess autonomic function

    24. effects of TEA on autonomic function [70 days]

      visit 1 in chronic phase; Composite Autonomic Symptoms Score (COMPASS) 31 survey visit 4 in chronic phase; will be used to assess autonomic function

    25. effects of TEA on autonomic function [1 day]

      baseline before the study; NE (indication of sympathetic activity) will be assessed using ELISA autonomic function.

    26. effects of TEA on autonomic function [28 days]

      baseline before the study; NE (indication of sympathetic activity) will be assessed using ELISA autonomic function.

    27. effects of TEA on autonomic function [42 days]

      baseline before the study; NE (indication of sympathetic activity) will be assessed using ELISA autonomic function.

    28. effects of TEA on autonomic function [70 days]

      baseline before the study; NE (indication of sympathetic activity) will be assessed using ELISA autonomic function.

    29. effects of TEA on autonomic function [1 day]

      30 minutes after the testing meal; NE (indication of sympathetic activity) will be assessed using ELISA autonomic function.

    30. effects of TEA on autonomic function [28 days]

      30 minutes after the testing meal; NE (indication of sympathetic activity) will be assessed using ELISA autonomic function.

    31. effects of TEA on autonomic function [42 days]

      30 minutes after the testing meal; NE (indication of sympathetic activity) will be assessed using ELISA autonomic function.

    32. effects of TEA on autonomic function [70 days]

      30 minutes after the testing meal; NE (indication of sympathetic activity) will be assessed using ELISA autonomic function.

    33. effects of TEA on autonomic function [1 day]

      60 minutes after the testing meal; NE (indication of sympathetic activity) will be assessed using ELISA autonomic function.

    34. effects of TEA on autonomic function [28 days]

      60 minutes after the testing meal; NE (indication of sympathetic activity) will be assessed using ELISA autonomic function.

    35. effects of TEA on autonomic function [42 days]

      60 minutes after the testing meal; NE (indication of sympathetic activity) will be assessed using ELISA autonomic function.

    36. effects of TEA on autonomic function [70 days]

      60 minutes after the testing meal; NE (indication of sympathetic activity) will be assessed using ELISA autonomic function.

    37. effects of TEA on autonomic function [1 day]

      baseline before the study; pancreatic polypeptide (PP, indication of vagal activity) will be assessed using ELISA autonomic function.

    38. effects of TEA on autonomic function [28 days]

      baseline before the study; pancreatic polypeptide (PP, indication of vagal activity) will be assessed using ELISA autonomic function.

    39. effects of TEA on autonomic function [42 days]

      baseline before the study; pancreatic polypeptide (PP, indication of vagal activity) will be assessed using ELISA autonomic function.

    40. effects of TEA on autonomic function [70 days]

      baseline before the study; pancreatic polypeptide (PP, indication of vagal activity) will be assessed using ELISA autonomic function.

    41. effects of TEA on autonomic function [1 day]

      30 minutes after the testing meal; pancreatic polypeptide (PP, indication of vagal activity) will be assessed using ELISA autonomic function.

    42. effects of TEA on autonomic function [28 days]

      30 minutes after the testing meal; pancreatic polypeptide (PP, indication of vagal activity) will be assessed using ELISA autonomic function.

    43. effects of TEA on autonomic function [42 days]

      30 minutes after the testing meal; pancreatic polypeptide (PP, indication of vagal activity) will be assessed using ELISA autonomic function.

    44. effects of TEA on autonomic function [70 days]

      30 minutes after the testing meal; pancreatic polypeptide (PP, indication of vagal activity) will be assessed using ELISA autonomic function.

    45. effects of TEA on autonomic function [1 day]

      60 minutes after the testing meal; pancreatic polypeptide (PP, indication of vagal activity) will be assessed using ELISA autonomic function.

    46. effects of TEA on autonomic function [28 days]

      60 minutes after the testing meal; pancreatic polypeptide (PP, indication of vagal activity) will be assessed using ELISA autonomic function.

    47. effects of TEA on autonomic function [42 days]

      60 minutes after the testing meal; pancreatic polypeptide (PP, indication of vagal activity) will be assessed using ELISA autonomic function.

    48. effects of TEA on autonomic function [70 days]

      60 minutes after the testing meal; pancreatic polypeptide (PP, indication of vagal activity) will be assessed using ELISA autonomic function.

    49. effects of TEA on GI hormones and inflammatory cytokine [1 day]

      baseline before the study; vasoactive intestinal peptide (VIP)

    50. effects of TEA on GI hormones and inflammatory cytokine [28 days]

      baseline before the study; vasoactive intestinal peptide (VIP)

    51. effects of TEA on GI hormones and inflammatory cytokine [42 days]

      baseline before the study; vasoactive intestinal peptide (VIP)

    52. effects of TEA on GI hormones and inflammatory cytokine [70 days]

      baseline before the study; vasoactive intestinal peptide (VIP)

    53. effects of TEA on GI hormones and inflammatory cytokine [1 day]

      30 minutes after the testing meal; vasoactive intestinal peptide (VIP)

    54. effects of TEA on GI hormones and inflammatory cytokine [28 days]

      30 minutes after the testing meal; vasoactive intestinal peptide (VIP)

    55. effects of TEA on GI hormones and inflammatory cytokine [42 days]

      30 minutes after the testing meal; vasoactive intestinal peptide (VIP)

    56. effects of TEA on GI hormones and inflammatory cytokine [70 days]

      30 minutes after the testing meal; vasoactive intestinal peptide (VIP)

    57. effects of TEA on GI hormones and inflammatory cytokine [1 day]

      60 minutes after the testing meal; vasoactive intestinal peptide (VIP)

    58. effects of TEA on GI hormones and inflammatory cytokine [28 days]

      60 minutes after the testing meal; vasoactive intestinal peptide (VIP)

    59. effects of TEA on GI hormones and inflammatory cytokine [42 days]

      60 minutes after the testing meal; vasoactive intestinal peptide (VIP)

    60. effects of TEA on GI hormones and inflammatory cytokine [70 days]

      60 minutes after the testing meal; vasoactive intestinal peptide (VIP)

    61. effects of TEA on GI hormones and inflammatory cytokine [day 1]

      baseline before the study; interleukin-10 (IL-10)

    62. effects of TEA on GI hormones and inflammatory cytokine [28 days]

      baseline before the study; interleukin-10 (IL-10)

    63. effects of TEA on GI hormones and inflammatory cytokine [42 days]

      baseline before the study; interleukin-10 (IL-10)

    64. effects of TEA on GI hormones and inflammatory cytokine [70 days]

      baseline before the study; interleukin-10 (IL-10)

    65. effects of TEA on GI hormones and inflammatory cytokine [1 day]

      30 minutes after the testing meal; interleukin-10 (IL-10)

    66. effects of TEA on GI hormones and inflammatory cytokine [28 days]

      30 minutes after the testing meal; interleukin-10 (IL-10)

    67. effects of TEA on GI hormones and inflammatory cytokine [42 days]

      30 minutes after the testing meal; interleukin-10 (IL-10)

    68. effects of TEA on GI hormones and inflammatory cytokine [70 days]

      30 minutes after the testing meal; interleukin-10 (IL-10)

    69. effects of TEA on GI hormones and inflammatory cytokine [1 day]

      60 minutes after the testing meal; interleukin-10 (IL-10)

    70. effects of TEA on GI hormones and inflammatory cytokine [28 days]

      60 minutes after the testing meal; interleukin-10 (IL-10)

    71. effects of TEA on GI hormones and inflammatory cytokine [42 days]

      60 minutes after the testing meal; interleukin-10 (IL-10)

    72. effects of TEA on GI hormones and inflammatory cytokine [70 days]

      60 minutes after the testing meal; interleukin-10 (IL-10)

    73. effects of TEA on GI hormones and inflammatory cytokine [1 day]

      baseline before the study; interferon α(IFNα)

    74. effects of TEA on GI hormones and inflammatory cytokine [28 days]

      baseline before the study; interferon α(IFNα)

    75. effects of TEA on GI hormones and inflammatory cytokine [42 days]

      baseline before the study; interferon α(IFNα)

    76. effects of TEA on GI hormones and inflammatory cytokine [70 days]

      baseline before the study; interferon α(IFNα)

    77. effects of TEA on GI hormones and inflammatory cytokine [1 day]

      30 minutes after the testing meal; interferon α(IFNα)

    78. effects of TEA on GI hormones and inflammatory cytokine [28 days]

      30 minutes after the testing meal; interferon α(IFNα)

    79. effects of TEA on GI hormones and inflammatory cytokine [42 days]

      30 minutes after the testing meal; interferon α(IFNα)

    80. effects of TEA on GI hormones and inflammatory cytokine [70 days]

      30 minutes after the testing meal; interferon α(IFNα)

    81. effects of TEA on GI hormones and inflammatory cytokine [1 day]

      60 minutes after the testing meal; interferon α(IFNα)

    82. effects of TEA on GI hormones and inflammatory cytokine [28 days]

      60 minutes after the testing meal; interferon α(IFNα)

    83. effects of TEA on GI hormones and inflammatory cytokine [42 days]

      60 minutes after the testing meal; interferon α(IFNα)

    84. effects of TEA on GI hormones and inflammatory cytokine [70 days]

      60 minutes after the testing meal; interferon α(IFNα)

    85. effects of TEA on GI hormones and inflammatory cytokine [1 day]

      baseline before the study; interleukin-1 beta (IL-1β)

    86. effects of TEA on GI hormones and inflammatory cytokine [28 days]

      baseline before the study; interleukin-1 beta (IL-1β)

    87. effects of TEA on GI hormones and inflammatory cytokine [42 days]

      baseline before the study; interleukin-1 beta (IL-1β)

    88. effects of TEA on GI hormones and inflammatory cytokine [70 days]

      baseline before the study; interleukin-1 beta (IL-1β)

    89. effects of TEA on GI hormones and inflammatory cytokine [1 day]

      30 minutes after the testing meal; interleukin-1 beta (IL-1β)

    90. effects of TEA on GI hormones and inflammatory cytokine [28 days]

      30 minutes after the testing meal; interleukin-1 beta (IL-1β)

    91. effects of TEA on GI hormones and inflammatory cytokine [42 days]

      30 minutes after the testing meal; interleukin-1 beta (IL-1β)

    92. effects of TEA on GI hormones and inflammatory cytokine [70 days]

      30 minutes after the testing meal; interleukin-1 beta (IL-1β)

    93. effects of TEA on GI hormones and inflammatory cytokine [1 day]

      60 minutes after the testing meal; interleukin-1 beta (IL-1β)

    94. effects of TEA on GI hormones and inflammatory cytokine [28 days]

      60 minutes after the testing meal; interleukin-1 beta (IL-1β)

    95. effects of TEA on GI hormones and inflammatory cytokine [42 days]

      60 minutes after the testing meal; interleukin-1 beta (IL-1β)

    96. effects of TEA on GI hormones and inflammatory cytokine [70 days]

      60 minutes after the testing meal; interleukin-1 beta (IL-1β)

    97. effects of TEA on GI hormones and inflammatory cytokine [1 day]

      baseline before the study; interleukin-6 (IL-6)

    98. effects of TEA on GI hormones and inflammatory cytokine [28 days]

      baseline before the study; interleukin-6 (IL-6)

    99. effects of TEA on GI hormones and inflammatory cytokine [42 days]

      baseline before the study; interleukin-6 (IL-6)

    100. effects of TEA on GI hormones and inflammatory cytokine [70 days]

      baseline before the study; interleukin-6 (IL-6)

    101. effects of TEA on GI hormones and inflammatory cytokine [1 day]

      30 minutes after the testing meal; interleukin-6 (IL-6)

    102. effects of TEA on GI hormones and inflammatory cytokine [28 days]

      30 minutes after the testing meal; interleukin-6 (IL-6)

    103. effects of TEA on GI hormones and inflammatory cytokine [42 days]

      30 minutes after the testing meal; interleukin-6 (IL-6)

    104. effects of TEA on GI hormones and inflammatory cytokine [70 days]

      30 minutes after the testing meal; interleukin-6 (IL-6)

    105. effects of TEA on GI hormones and inflammatory cytokine [1 day]

      60 minutes after the testing meal; interleukin-6 (IL-6)

    106. effects of TEA on GI hormones and inflammatory cytokine [28 days]

      60 minutes after the testing meal; interleukin-6 (IL-6)

    107. effects of TEA on GI hormones and inflammatory cytokine [42 days]

      60 minutes after the testing meal; interleukin-6 (IL-6)

    108. effects of TEA on GI hormones and inflammatory cytokine [70 days]

      60 minutes after the testing meal; interleukin-6 (IL-6)

    109. effects of TEA on GI hormones and inflammatory cytokine [day 1]

      baseline before the study; tumor necrosis factor alpha(TNFα)

    110. effects of TEA on GI hormones and inflammatory cytokine [28 days]

      baseline before the study; tumor necrosis factor alpha(TNFα)

    111. effects of TEA on GI hormones and inflammatory cytokine [42 days]

      baseline before the study; tumor necrosis factor alpha(TNFα)

    112. effects of TEA on GI hormones and inflammatory cytokine [70 days]

      baseline before the study; tumor necrosis factor alpha(TNFα)

    113. effects of TEA on GI hormones and inflammatory cytokine [1 day]

      30 minutes after the testing meal; tumor necrosis factor alpha(TNFα)

    114. effects of TEA on GI hormones and inflammatory cytokine [28 days]

      30 minutes after the testing meal; tumor necrosis factor alpha(TNFα)

    115. effects of TEA on GI hormones and inflammatory cytokine [42 days]

      30 minutes after the testing meal; tumor necrosis factor alpha(TNFα)

    116. effects of TEA on GI hormones and inflammatory cytokine [70 days]

      30 minutes after the testing meal; tumor necrosis factor alpha(TNFα)

    117. effects of TEA on GI hormones and inflammatory cytokine [1 day]

      60 minutes after the testing meal; tumor necrosis factor alpha(TNFα)

    118. effects of TEA on GI hormones and inflammatory cytokine [28 days]

      60 minutes after the testing meal; tumor necrosis factor alpha(TNFα)

    119. effects of TEA on GI hormones and inflammatory cytokine [42 days]

      60 minutes after the testing meal; tumor necrosis factor alpha(TNFα)

    120. effects of TEA on GI hormones and inflammatory cytokine [70 days]

      60 minutes after the testing meal; tumor necrosis factor alpha(TNFα)

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • No any systemic diseases;

    • no scleroderma; no history of gastrointestinal surgery;

    • no dyspeptic symptoms during the past 2 weeks;

    • not taking any medications except contraceptives during the past 2 weeks;

    • age 18 and older.

    Exclusion Criteria:
    • History of any systemic diseases or surgeries;

    • allergic to adhesives; pregnancy;

    • unable to sign the consent form.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Johns Hopkins Bayview Medical Center Baltimore Maryland United States 21224

    Sponsors and Collaborators

    • Johns Hopkins University

    Investigators

    • Principal Investigator: Jiande Chen, Ph.D, Johns Hopkins University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Johns Hopkins University
    ClinicalTrials.gov Identifier:
    NCT03294616
    Other Study ID Numbers:
    • IRB00089514
    First Posted:
    Sep 27, 2017
    Last Update Posted:
    Nov 26, 2019
    Last Verified:
    Nov 1, 2019
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Johns Hopkins University
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Nov 26, 2019